ArticleCancer biology & therapy2015

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Tracy C Okoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.